Sign in
Not yet recruitingPhase 3

Early Corticosteroids in Severe Influenza Pneumonia

Key facts

Who runs it
Centre Hospitalier Régional Metz-Thionville
Where
France48 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
544 people, planned
Started
Sept 2026
Expected to end
Dec 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Dexametasone
  • Sodium chloride 0.9% (placebo)
Record updated
28 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Age ≥ 18 y
  • Admission to ICU or intermediate care for less than 2 days
  • Admission to hospital for less than 5 days
  • Diagnosis of influenza pneumonia with; PCR positive for Influenza dated less than 5 days; AND focal shadowing/infiltrates on chest X-ray or CT-scan; AND at least one of the following: cough, purulent sputum, chest pain or dyspnoea
  • Requirement of supplemental oxygen at a flow rate of at least 3L/min OR non-invasive ventilation OR high flow oxygen therapy OR invasive mechanical ventilation
  • Written informed or emergency consent
  • Ongoing medical insurance

Who cannot take part

  • Bone marrow transplant or chemotherapy-induced neutropenia
  • Subject with shock on enrolment and on ongoing vasopressor therapy (≥ 0.25 microg/kg/min)
  • Indication for corticosteroid therapy in a dosage above 0.5mg/kg/day prednisone-equivalent
  • Known allergy to dexamethasone or to one of its excipients
  • Co-infection with COVID-19
  • Known active tuberculosis or fungal infection
  • Active viral hepatitis or active herpes virus infection
  • Moribund state
  • Uncontrolled psychotic states
  • Pheochromocytoma
  • Cardiogenic shock secondary to influenza myocarditis
  • Patient at risk of strongyloidiasis
  • Subject deprived of liberty or under a legal protective measure (example: patients under guardianship or curatorship)
  • Pregnant or breastfeeding woman
  • Lack of clinical equipoise by the attending physician and/or the presence of a substantial risk associated with the patients' participation in the trial

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a Phase III, multicentre, randomized, controlled, double-blind, superiority trial aiming to evaluate the efficacy of dexamethasone versus placebo in patients admitted to intensive care or intermediate care with influenza and hypoxemic acute respiratory failure. Patients will receive state-of-the-art standard therapy for severe influenza. They will be randomized in a 1:1 ratio to one of the two arms. Patients, investigators and care providers will be blinded to the patient arm. Patients will receive antiviral treatment and antibiotic therapy if bacterial co-infection is suspected. All clinical interventions such as use of ventilatory strategy, laboratory tests, and hemodynamic management will be left at the discretion of the team in both arms. Special attention will be given to the prompt diagnosis and management of aspergillosis, with investigators provided with decision support tools and algorithms based on the most recent definition (i.e., FUNDICU). Patients will be followed for up to 28 days after enrolment and national registries will be used for 90-day vital status assessment. Telephone calls will be made on day 90 to assess quality of life.

The 2 groups in the trial

  • DexamethasoneTreatment being tested

    a daily dose of 6 mg dexamethasone (investigational medicinal product) suspended in sodium chloride 0.9% and administered as a masked intravenous injection (total volume of 5 ml) once daily for up to 10 days from randomization OR until discharge from the participating intensive care or intermediate care unit.

    Treatment: Dexametasone

  • PlaceboPlacebo, for comparison

    a daily dose of placebo (sodium chloride 0.9%, total volume of 5 ml) intravenously once daily for up to 10 days from randomization OR until discharge from the participating intensive care or intermediate care unit.

    Treatment: Sodium chloride 0.9% (placebo)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Early Corticosteroids in Severe Influenza Pneumonia, a Phase III Randomized Controlled Trial
Record updated
28 August 2026